RESUMEN
CASE DESCRIPTION: A 7-year-old gray Mustang gelding weighing 454 kg was presented for evaluation of a brown mass within the left eye (OS) of 1 year's duration with recent enlargement. CLINICAL FINDINGS: A nonpainful, 8 mm diameter, brown, vascularized mass was identified in the anterior chamber of the OS. Ocular B-scan ultrasound confirmed iris involvement and corneal endothelial contact. Histopathology confirmed the presumptive diagnosis of a uveal melanocytic neoplasm, and revealed 1-3 mitotic figures per high power (400x) field. TREATMENT AND OUTCOME: The mass was removed via sector iridectomy without complications, but without complete margins. Three cutaneous melanocytomas noted 1.5 months postoperatively were completely excised. No tumor regrowth was noted 15 months postoperatively, supporting a diagnosis of melanocytoma for the iridal mass. CLINICAL RELEVANCE: Sector iridectomy is a reasonable treatment option for uncomplicated iridal melanocytomas in horses. Mitotic index and presence of cutaneous melanocytic neoplasms may be irrelevant to the prognosis of equine iridal melanocytic neoplasms.
Asunto(s)
Enfermedades de los Caballos/cirugía , Iridectomía/veterinaria , Neoplasias del Iris/veterinaria , Nevo Pigmentado/veterinaria , Animales , Segmento Anterior del Ojo/patología , Segmento Anterior del Ojo/cirugía , Enfermedades de los Caballos/patología , Caballos , Iridectomía/métodos , Neoplasias del Iris/patología , Neoplasias del Iris/cirugía , Masculino , Nevo Pigmentado/patología , Nevo Pigmentado/cirugía , Resultado del TratamientoRESUMEN
OBJECTIVE: To evaluate the in vitro efficacy of an ophthalmic drug combination against common corneal pathogens of horses. SAMPLE POPULATION: Representative isolates of 3 bacterial and 2 fungal corneal pathogens of horses. PROCEDURES: Pathogens were subjected to minimum inhibitory concentration (MIC) testing of a drug combination that consisted of equal volumes of natamycin 3.33%, tobramycin 0.3%, cefazolin 5.5%, and equine serum. Proteinase inhibitory activity of the drug combination was assessed by use of a fluorescence microplate assay with gelatin and collagen I as substrates. The MICs of the drug combination were compared with those for each of the component medications and antiproteinase activity of the drug combination was compared with that of serum by use of paired t tests and a 2-way ANOVA, respectively. RESULTS: The drug combination was at least as effective as each medication separately for inhibiting microbial growth of all pathogens tested and was significantly more effective against B-hemolytic Streptococcus spp, Aspergillus spp, and Fusarium spp than the relevant medications separately. Serum and the drug combination both had significant antigelatinase activity, and serum had significant anticollagenase activity. Antiproteinase activity of serum was a concentration-dependent event, which enabled serum to achieve significantly greater activity than the drug combination after 3.5 and 4 hours of incubation [corrected] for the gelatin and collagen I assays, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: Drug combinations have the attractive potential of minimizing the time, stress, and fatigue associated with topical treatment regimens consisting of multiple drugs used separately for horses with keratitis.
Asunto(s)
Antibacterianos/administración & dosificación , Antifúngicos/administración & dosificación , Aspergillus/efectos de los fármacos , Bacterias/efectos de los fármacos , Fusarium/efectos de los fármacos , Enfermedades de los Caballos/microbiología , Animales , Antibacterianos/farmacología , Antifúngicos/farmacología , Infecciones Bacterianas/microbiología , Infecciones Bacterianas/veterinaria , Cefazolina/administración & dosificación , Cefazolina/farmacología , Enfermedades de la Córnea/microbiología , Enfermedades de la Córnea/veterinaria , Combinación de Medicamentos , Caballos , Pruebas de Sensibilidad Microbiana , Micosis/microbiología , Micosis/veterinaria , Natamicina/administración & dosificación , Natamicina/farmacología , Inhibidores de Proteasas/administración & dosificación , Inhibidores de Proteasas/farmacología , Pseudomonas aeruginosa/efectos de los fármacos , Staphylococcus aureus/efectos de los fármacos , Streptococcus/efectos de los fármacos , Tobramicina/administración & dosificación , Tobramicina/farmacologíaRESUMEN
Lufenuron is a benzoylphenyl urea-derived insecticide that has been recently introduced as a novel treatment for fungal infections in horses. The purposes of this study were to determine (1) the in vitro efficacy of lufenuron against Aspergillus and Fusarium spp. and (2) the ability of lufenuron to reach efficacious blood concentrations after PO administration in horses. Fungal colonies isolated from diseased equine corneas were tested against lufenuron solutions up to 700 microg/mL. Twenty-one adult horses received 1 of 3 PO lufenuron treatment regimens: 5 mg/kg body weight (BW) q24h for 3 days, 20 mg/kg BW q24h for 3 days, or 60 mg/ kg BW q24h for 1 day. Blood samples were collected up to 96 hours after drug administration and analyzed by high-performance liquid chromatography. Statistical analyses of lufenuron blood concentrations were performed by analysis of variance and Fischer's Least Significant Difference test, with statistical significance set at P < .05. Lufenuron showed no effect on the in vitro growth of Aspergillus or Fusarium spp. Lufenuron was detected in the blood of all but 1 horse and showed no adverse effects. The maximum blood lufenuron concentration (83.5 +/- 58.7 microg/L) was lower than the concentrations proven to be ineffective in vitro in this study. Further therapeutic use of lufenuron as an antifungal agent in horses should be based on proven efficacy against specific strains of clinically relevant fungi with pharmacokinetic data demonstrating sufficient lufenuron concentrations in target tissues.
Asunto(s)
Aspergillus/efectos de los fármacos , Benzamidas/sangre , Benzamidas/farmacología , Fusarium/efectos de los fármacos , Caballos/microbiología , Insecticidas/farmacología , Administración Oral , Animales , Benzamidas/administración & dosificación , Benzamidas/farmacocinética , Femenino , Insecticidas/administración & dosificación , Insecticidas/sangre , Insecticidas/farmacocinética , MasculinoRESUMEN
An 18-year-old Spanish Mustang mare was referred for evaluation of progressive weight loss and persistent hyperglycemia. Clinicopathologic abnormalities included marked hyperglycemia and glycosuria. Serum cortisol concentration was appropriately decreased following administration of dexamethasone, indicating that the horse did not have pituitary pars intermedia dysfunction. Serum insulin and plasma C-peptide concentrations were low, suggesting that hyperglycemia was a result of decreased secretion of insulin by pancreatic beta cells. In addition, glucose concentration did not return to the baseline concentration until 5 hours after i.v. administration of a glucose bolus, suggesting that insulin secretion, insulin effect, or both were reduced. However, i.v. administration of insulin caused only a slight decrease in the plasma glucose concentration, giving the impression that the action of insulin was impaired. Within 5 hours after administration of a combination of glyburide and metformin, which is used to treat diabetes mellitus in humans, the glucose concentration was within reference limits. The horse was euthanized, and a postmortem examination was done. Immunohistochemical staining of sections of the pancreas revealed attenuation of the pancreatic islet beta-cell population, with beta cells that remained generally limited to the periphery of the islets. These findings indicate that, albeit rare, pancreatic beta-cell failure may contribute to the development of diabetes mellitus in horses.
Asunto(s)
Glucemia/metabolismo , Diabetes Mellitus/veterinaria , Gliburida/uso terapéutico , Enfermedades de los Caballos/diagnóstico , Hipoglucemiantes/uso terapéutico , Islotes Pancreáticos/fisiopatología , Metformina/uso terapéutico , Animales , Área Bajo la Curva , Diabetes Mellitus/sangre , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/tratamiento farmacológico , Femenino , Enfermedades de los Caballos/sangre , Enfermedades de los Caballos/tratamiento farmacológico , Caballos , Resultado del TratamientoRESUMEN
An 11-year-old Quarterhorse mare developed a paranasal sinus osteoma that extended into the right orbit and led to ipsilateral exophthalmia. Although the tumor was radiographically evident in the paranasal sinuses, ultrasonography was used to demonstrate extension of the tumor into the retrobulbar space, and endoscopy was used to identify its extension into the nasopharynx. Biopsies were obtained using both fine-needle aspiration and paranasal sinus trephination. Despite numerous antemortem diagnostic tests, only postmortem histologic analysis of the mass afforded the diagnosis of osteoma.